Good Karma in Biotech and Pharma
American pharmaceutical giant Eli Lilly is radically expanding its presence in Germany.
That’s great news for the country, which sees biotech and pharmaceuticals as one of its
main pillars for the years to come.
Your company is already operating in Germany and you would now like to export worldwide?
American pharmaceutical giant Eli Lilly is radically expanding its presence in Germany.
That’s great news for the country, which sees biotech and pharmaceuticals as one of its
main pillars for the years to come.
Germany’s healthcare sector is benefiting from major investments in new gene and cell therapy research and development sites.
The pharmaceuticals and chemicals giant is investing a hefty nine-figure in a state-of-the-art facility in its home city of Darmstadt.
AbbVie is building an ultra-modern research and office facility in the western German city of Ludwigshafen.
The High-Tech Gründerfonds (HTGF) will sell its shares in start-up Cardior Pharmaceuticals as part of a billion-euro acquisition by industry giant Novo Nordisk.
The Japanese pharmaceutical giant will expand its Pfaffenhofen location in southern Germany into an international innovation center.
Germany’s healthcare sector enjoyed a successful year with a resurgent biotech sector generating a quarter of new capital. New therapies are being developed for a range of autoimmune diseases and telemedicine service are on the rise.
The injectable Mounjaro that will be mass produced by Eli Lilly and Company in Germany has been cleared for use in helping people shed pounds.
In 2023, there was a notable resurgence in the financing available to Germany's biotechnology sector.
Germany is undertaking a “digital revolution” in healthcare and now has a strategy to make life easier for pharmaceutical companies.